Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01275 (
glucagon
)
26,492
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The large number of amacrine cells which contain
gamma-aminobutyric acid
(
GABA
) in the turtle retina makes it difficult to examine specific GABAergic cell types. In order to selectively label subpopulations of GABAergic neurons, we have used fluorescent double-labeling immunocytochemical techniques to examine the localization of
GABA
-like immunoreactivity (LI) in amacrine cells which contain antigens resembling the neuropeptides
glucagon
(
GLUC
), corticotropin-releasing factor (CRF) or enkephalin (ENK).
GABA
-LI was found in 41% of the cells with
GLUC
-, 100% of the cells with CRF-, and 69% of the cells with ENK-LI. There were regional differences in the presence of
GABA
-LI in amacrine cell populations with ENK-LI.
GABA
-LI was present in about 80% of the cells with ENK-LI outside of the visual streak, while only 37% of the cells within the streak had
GABA
-LI. Based on the distinct morphologies and regional distributions of these peptidergic amacrine cells, we conclude that they represent different subpopulations of GABAergic amacrine cells in the turtle retina. Future studies can now utilize existing information regarding the synaptic connectivity of these peptidergic amacrine cells to help delineate the functions of GABAergic amacrine cells in the turtle retina.
...
PMID:Colocalization of enkephalin-, glucagon-, and corticotropin-releasing factor-like immunoreactivity in GABAergic amacrine cells in turtle retina. 146 2
The present study was aimed at localizing
gamma-aminobutyric acid
(
GABA
) and its enzyme of synthesis, glutamic acid decarboxylase (GAD), in the mouse pancreas by immunocytochemical methods. The influence of
GABA
on hormone release was also studied with normal mouse and rat islets and the isolated perfused rat pancreas. Particular attention was paid to
glucagon
release to test a recent hypothesis suggesting that
GABA
mediates the still unexplained glucose-induced inhibition of
glucagon
release.
GABA
and GAD were identified only in islet cells and never in the exocrine tissue. Exogenous
GABA
, baclofen (agonist of GABAB receptors), muscimol (agonist of GABAA receptors), or bicuculline (antagonist of GABAA receptors) did not affect insulin and somatostatin release by isolated mouse or rat islets.
GABA
was also without effect on glucose-induced electrical activity in mouse B-cells.
Glucagon
secretion by mouse islets was only slightly inhibited (approximately 20%) by
GABA
. Since muscimol had a similar effect, and baclofen was ineffective, the inhibition by
GABA
probably involves GABAA receptor activation. Bicuculline, however, did not antagonize the inhibitory effects of
GABA
and muscimol, probably because the antagonist alone also decreased
glucagon
secretion. In contrast to
GABA
, low (3 mM) and high (20 mM) concentrations of glucose strongly inhibited (approximately 50-65%)
glucagon
release; this inhibition was not prevented by bicuculline. Similar results were obtained with the perfused rat pancreas; muscimol slightly inhibited
glucagon
release under various conditions, and bicuculline did not reverse the strong inhibition produced by 16.7 mM glucose. In conclusion,
GABA
does not affect insulin and somatostatin secretion, but inhibits A-cells, probably by acting on GABAA receptors. It is unlikely, however, that this small inhibitory effect can account for the inhibition of
glucagon
release produced by glucose.
...
PMID:The influence of gamma-aminobutyric acid on hormone release by the mouse and rat endocrine pancreas. 168 37
The endocrine part of the pancreas plays a central role in blood-glucose regulation. It is well established that an elevation of glucose concentration reduces secretion of the hyperglycaemia-associated hormone
glucagon
from pancreatic alpha 2 cells. The mechanisms involved, however, remain unknown. Electrophysiological studies have demonstrated that alpha 2 cells generate Ca2+-dependent action potentials. The frequency of these action potentials, which increases under conditions that stimulate
glucagon
release, is not affected by glucose or insulin. The inhibitory neurotransmitter
gamma-aminobutyric acid
(
GABA
) is present in the endocrine part of the pancreas at concentrations comparable to those encountered in the central nervous system, and co-localizes with insulin in pancreatic beta cells. We now describe a mechanism whereby
GABA
, co-secreted with insulin from beta cells, may mediate part of the inhibitory action of glucose on
glucagon
secretion by activating GABAA-receptor Cl- channels in alpha 2 cells. These observations provide a model for feedback regulation of
glucagon
release, which may be of significance for the understanding of the hypersecretion of
glucagon
frequently associated with diabetes.
...
PMID:Glucose-inhibition of glucagon secretion involves activation of GABAA-receptor chloride channels. 255 Aug 26
Specific somatostatin (SRIH) receptors on human pituitary adenoma cell membranes were characterized using [125I]Tyr11-SRIH as the radioligand. Specific binding of [125I] Tyr11-SRIH to adenoma cell membranes reached a steady state within 30 min at 25 C, and semilogarithmic analysis of the data revealed that the rate of the binding was linear at 25 C with a t1/2 of 13.2 min. Specific binding increased linearly with 5-160 micrograms plasma membrane protein. SRIH-14 and SRIH-28 inhibited [125I]Tyr11-SRIH binding to adenoma cell membranes with ID50S of 0.32 and 0.50 nM, respectively, while secretin,
glucagon
, gastrin, cholecystokinin-8, bombesin, TRH, LHRH, human GH-releasing factor-(1-44)-NH2, D-Ala2-met-enkephalin,
gamma-aminobutyric acid
and taurine did not significantly inhibit binding. All of 13 GH-secreting adenomas investigated had specific and high affinity SRIH receptors, with a dissociation constant (Kd) of 0.80 +/- 0.15 nM (mean +/- SEM) and a maximal binding capacity (Bmax) of 234.2 +/- 86.9 fmol/mg protein (mean +/- SEM). Among five of the nonsecreting pituitary adenomas examined, two had SRIH receptors with Kd values of 0.18 and 0.32 nM and Bmax values of 17.2 and 48.0 fmol/mg protein, respectively. In the remaining three, SRIH receptors were not detected. These results indicate that GH-secreting adenomas as well as some nonfunctioning adenomas have specific SRIH receptors, and hence, the function of the adenomas could be altered by SRIH.
...
PMID:Specific somatostatin receptors on human pituitary adenoma cell membranes. 286 81
Studies of brain monoamines and neuropeptides have provided extensive evidence in support of their role in the control of normal eating behavior. In this process, the medial and lateral portions of the hypothalamus, working in conjunction with forebrain and hindbrain sites and with peripheral autonomic-endocrine systems, have a critical responsibility in balancing signals for hunger and satiety. Via its rich and biologically active neurotransmitter substances, the hypothalamus monitors and integrates the complex sensory and metabolic input concerning the nutritional status of the organism and transduces this information into appropriate quantitative and qualitative adjustments in food intake. The specific neurotransmitters for which there is the most extensive evidence for a physiological function include the eating-stimulatory substances norepinephrine (alpha 2), opioid peptides, pancreatic polypeptides, growth hormone-releasing factor, and
gamma-aminobutyric acid
; the eating-inhibitory substances dopamine, epinephrine, serotonin, cholecystokinin, neurotensin, calcitonin,
glucagon
, and corticotropin-releasing factor; and possibly other gut-brain peptides. From biochemical, pharmacological, and anatomical studies, hypotheses have been generated to explain the role of these various monoamines and neuropeptides in controlling total energy intake, in determining the amount and pattern of macronutrient selection, and in maintaining normal energy and nutrient stores under fluctuating conditions within the external environment.
...
PMID:Brain monoamines and peptides: role in the control of eating behavior. 286 77
The cellular and subcellular distribution of L-glutamate decarboxylase (GAD), the biosynthetic enzyme for
gamma-aminobutyric acid
(
GABA
), was determined immunohistochemically in rat pancreatic islet using light and electron microscopic techniques. The cellular distribution of GAD was determined at the light microscopic level using an elution/re-staining protocol and a computerized digital image processing technique. At this level of resolution, immunofluorescent GAD was observed to be co-localized with immunofluorescent insulin in the islet B-cells and absent in both the A-cells, which contained
glucagon
, and the D-cells, which contained somatostatin. Subcellular localization of GAD was determined using an electron microscopic, colloidal gold post-embedding protocol and was compared to insulin immunoreactivity in serial sections of the same B-cell. In the same islet B-cell, GAD immunoreactivity appeared predominantly in the extragranular cytoplasm, whereas insulin immunoreactivity was associated with the secretory granules. Quantitative analysis of GAD immunoreactivity in the B-cell revealed 15.3 +/- 1.8 gold particles/micron2 in the cytoplasm, 1.7 +/- 0.2 gold particles/micron2 in the secretory granules, and 0.4 +/- 0.4 gold particles/micron2 in the mitochondria. The results of this study, localization of the biosynthetic enzyme for
GABA
to the B-cell cytoplasmic compartment and its absence in the secretory granules which contain insulin, are compatible with the hypothesis that
GABA
functions as an intracellular mediator of B-cell activity.
...
PMID:Cellular and subcellular immunolocalization of L-glutamate decarboxylase in rat pancreatic islets. 289 76
The immunocytochemical localization of several substances with putative neurotransmitter or modulator properties was investigated in the retinae of three urodele species.
Gamma-aminobutyric acid
-like immunoreactive labelling appeared in different types of amacrine and horizontal cells. In addition, labelled fibres in the optic nerve were detected. It was not possible to determine whether these fibres were ganglion-cell axons or part of an efferent projection. Endogenous serotonin was found in several populations of amacrine cells including stratified and diffuse types.
Glucagon
-like immunoreactivity appeared in one bistratified amacrine cell type, and neurotensin-like immunoreactivity was detected in a single monostratified amacrine cell type. Metenkephalin-like-immunoreactive labelling was type. Metenkephalin-like-immunoreactive labelling was rare but found in several sublaminae of the inner plexiform layer. Thus each peptide-like-immunoreactive cell type makes up a distinct and unique population of cells and probably has a special functional role in retinal processing. There are striking similarities in the peptide-like immunoreactive patterns of Triturus alpestris and Necturus maculosus whereas in Ambystomatidae the peptide-like-immunoreactive systems appear to be differently organized. This supports the hypothesis that Salamandridae and Proteidae are more closely related to each other than to the Ambystomatidae.
...
PMID:Putative neurotransmitters in the retinae of three urodele species (Triturus alpestris, Salamandra salamandra, Pleurodeles waltli). 289 93
Neuropeptides and biogenic amines known to be present in neurons or afferent terminals in the paraventricular nucleus (PVH), supraoptic nucleus (SON) and/or lateral hypothalamus (LH) were added to small areas of these structures obtained by micropuncture and cyclic adenosine monophosphate (cAMP) levels were measured. cAMP accumulation occurred in PVH, SON and LH in response to neuropeptides of the secretin family, such as vasoactive intestinal peptide (VIP) and in response to catecholamines. Bradykinin, alpha-melanocyte-stimulating (alpha-MSH), luteinizing hormone-releasing hormone (LH-RH), oxytocin and carbamylcholine stimulated cAMP accumulation selectively in one or two of the above structures.
Glucagon
, cholecystokinin (CCK), somatostatin (SRIF), corticotropin-releasing factor (CRF), thyrotropin-releasing hormone (TRH), adrenocorticotropin (ACTH), melanocyte-stimulating hormone (MSH), methionine enkephalin (Met-Enk), beta-endorphin, neurotensin, bombesin and angiotensin II did not effect cAMP levels while leucine enkephalin (Leu-Enk), arginine vasopressin and
gamma-aminobutyric acid
(
GABA
) elicited regionally selective decreases in basal levels of cAMP. When interactions between some of these compounds were measured, VIP and norepinephrine exerted a more than additive effect on cAMP elevation in the PVH, while the effect on cAMP of the SON and LH was additive.
...
PMID:Interaction of neuropeptides and biogenic amines on cyclic adenosine monophosphate accumulation in hypothalamic nuclei. 300 57
To evaluate whether the
gamma-aminobutyric acid
(
GABA
)ergic system plays a role in the defective insulin secretion in human diabetes mellitus, 15 non-insulin-dependent diabetics with fasting hyperglycemia above 140 mg/dl were submitted to two consecutive i.v. glucose tolerance tests (IVGTT) (0.33 g/kg b.w.), in basal conditions and after pharmacologic activation of the
GABA
system with baclofen and sodium valproate. Baclofen, a synthetic analogue, was given to 8 diabetics in two divided doses of 10 mg each 8h and 1h before the post-treatment test; sodium valproate, a drug that increases endogenous
GABA
activity, was given orally (800 mg) 60 min before the performance of the post-treatment IVGTT. Neither treatment brought about significant changes in insulin, C-peptide,
glucagon
or growth hormone responses to i.v. glucose nor did they significantly change glucose disappearance rates. These results seem to indicate that
GABA
does not play a major role in the pathogenesis of defective insulin secretion in non-insulin-dependent diabetes mellitus.
...
PMID:Impaired insulin secretion in human diabetes mellitus. Effect of pharmacological activation of gamma-aminobutyric acid system. 301 23
The effects of
gamma-aminobutyric acid
(
GABA
) on the secretion of insulin,
glucagon
, and somatostatin were studied in the isolated dog pancreas. Insulin secretion was inhibited in a dose-related fashion for 10 min or more by as little as 1 microM
GABA
. A prompt but small and transitory rise in somatostatin secretion, lasting only 1 min, occurred at
GABA
concentrations of 10 and 100 microM, levels that exert inhibitory effects on nervous tissue. Bicuculline, a
GABA
antagonist, inhibited insulin secretion and did not antagonize
GABA
-mediated insulin inhibition. The results suggest that
GABA
in concentrations that are known to exist in islet tissue can influence the secretion of islet hormones.
...
PMID:Effects of gamma-aminobutyric acid on insulin, glucagon, and somatostatin release from isolated perfused dog pancreas. 613 11
1
2
3
4
5
Next >>